November 2008 Drug Protein Targets
solute carrier family 6 (neurotransmitter transporter, L-proline), member 7
Also known as SLC6A7 or PROT, this protein is a member of the GABA neurotransmitter family. It is a brain L-proline transporter protein.
- Lexicon Pharmaceuticals is developing an orally-active, small-molecule inhibitor of SLC6A7, as a cognition enhancer for the treatment of Alzheimer's disease.
- SLC6A7 belongs to the Transporter > Porters (uni-, sym- and anti-) Target Family Group. Its Entrez Gene ID is 6534.
microRNA 296
Also known MIRN296 or miR-296, research suggests that increased expression of miR-296 in tumours represses hepatocyte growth factor-regulated tyrosine kinase substrate expression and pathways involving VEGFR and PDGFR.
- Regulus Therapeutics is developing an antisense oligonucleotide directed against miR-296, for the treatment of cancer.
- Its Entrez Gene ID is 407022.
retinoic acid receptor responder (tazarotene induced) 3
Retinoic acid receptor responder (tazarotene induced) 3 (RIG-I) is a class II tumour suppressor gene. Activation of RIG-I is thought to induce type-I interferon and natural killer cell responses. Involvement in detection and eradication of replicating viral genomes has also been suggested.
- Alnylam is developing a dual-activity small interfering RNA which both inhibit bcl-2 and activate RIG-I as anticancers.
- Its Entrez Gene ID is 5920.
CD27 molecule
This member of the TNF-receptor superfamily binds CD70 and regulates B-cell proliferation by T-cells and T-cell activation. Involvement in apoptosis through SIVA1 has also been documented.
- Celldex Therapeutics is developing anti-CD27 antibodies, for the treatment of cancer.
- CD27 belongs to the Receptor Target Family Group. Its Entrez Gene ID is 939.
Pharmaprojects - New protein targets for drug development
© Informa UK Ltd 2008
Registered Office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK.
Registered in England and Wales No: 1072954
